Annals of Cardiothoracic Surgery · 2022 · 12 citations · 30 references
MedicineCardiologySurgeryCardiothoracic SurgeryMedical RoboticsSurvival AnalysisCardiac Valve SurgeryMitral RegurgitationMitral Valve DiseaseRobot-assisted SurgeryRobotic Cardiothoracic SurgerySurgical RoboticsKaplan-meier Confidence IntervalsMitral Regurgitation Severity AssessmentOverall MortalityRecurrence After RepairResidual Mitral RegurgitationRobot-assisted Valve RepairRobot-assisted Valve SurgeryRobotic Mitral Valve Surgery
Background: Over the past two decades surgical approaches for mitral valve (MV) disease have evolved with the advent of minimally invasive techniques. Robotic mitral valve repair (RMVr) safety and efficacy has been well documented, however, mid- to long-term data are limited. The aim of this review was to provide a comprehensive analysis of the available mid- to long-term data for RMVr. Methods: Electronic searches of five databases were performed to identify all relevant studies reporting minimum five-year data on RMVr. Pre-defined primary outcomes of interest were overall survival, freedom from MV reoperation and from moderate or worse mitral regurgitation (MR) at five years or more post-RMVr. A meta-analysis of proportions or means was performed, utilizing a random effects model, to present the data. Kaplan-Meier curves were aggregated using reconstructed individual patient data. Results: Nine studies totaling 3,300 patients undergoing RMVr were identified. Rates of overall survival at 1-, 5- and 10-year were 99.2%, 97.4% and 92.3%, respectively. Freedom from MV reoperation at eight-years post RMVr was 95.0%. Freedom from moderate or worse MR at seven years was 86.0%. Rates of early post-operative complications were low with only 0.2% all-cause mortality and 1.0% cerebrovascular accident. Reoperation for bleeding was low at 2.2% and successful RMVr was 99.8%. Mean intensive care unit and hospital stay were 22.4 hours and 5.2 days, respectively. Conclusions: RMVr is a safe procedure with low rates of early mortality and other complications. It can be performed with low complication rates in high volume, experienced centers. Evaluation of available mid-term data post-RMVr suggests favorable rates of overall survival, freedom from MV reoperation and from moderate or worse MR recurrence.
30
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page, Joanne E. McKenzie, Patrick M. Bossuyt et al. · BMJ · 2021 · 95K citations · Full text
2017 ESC/EACTS Guidelines for the management of valvular heart disease
Helmut Baumgartner, Volkmar Falk, Jeroen J. Bax et al. · European Heart Journal · 2017 · 6.3K citations · Full text
Medicine, Cardiology, Surgery +14
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page, Joanne E. McKenzie, Patrick M. Bossuyt et al. · 2020 · 5.3K citations · Full text